Immunotherapy | Topics

High Tumor Mutation Burden Predicts Response to Immune Checkpoint Blockade for Some Cancer Types
April 03, 2021

Data investigating the predictive capabilities of high tumor mutation burden found it to be predictive of response to immune checkpoint blockade in some, but not all, types of cancers.

Updated Data Announced for Both COM701 Monotherapy and in Combination with Nivolumab
March 19, 2021

Compugen announced updated data surrounding the investigational therapeutic antibody, COM701, as monotherapy and in combination with nivolumab.

Oncolytic Virus TILT-123 Appears Safe, According to Preliminary Results of First-in-Human Trial
March 17, 2021

Recently reported results from the ongoing phase 1 TUNINTIL trial of the oncolytic virus TILT-123 show safety of this approach.